Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Bremelanotide (PT-141 / Vyleesi) is FDA approved for hypoactive sexual desire disorder in premenopausal women and activates melanocortin receptors to enhance sexual desire and arousal
The dosing framework on this page is based on the published Phase 2 trial (Jastreboff et al., 2023, NEJM ) and the Rosenstock et al
The potential effects on fetal development and breast milk composition are unknown
Fat freezing Birmingham results are permanent because destroyed fat cells cannot regenerate
A recent agreement between Lilly and U.S
Even when weight thresholds are met, a medical assessment of benefit, risks, contraindications and follow-up is still required
US$ 28.43
US$ 20.14
US$ 20.84
US$ 29.64
